Quick Answer
Avalo Therapeutics, Inc. reported Total Assets of $116.46 million for fiscal year 2025.
Avalo Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $116.46M | -22.7% |
| 2024 | $150.73M | +618.0% |
| 2023 | $20.99M | -37.1% |
| 2022 | $33.37M | -58.4% |
| 2021 | $80.21M | +83.3% |
| 2020 | $43.76M | +21.2% |
| 2019 | $36.11M | -48.6% |
| 2018 | $70.25M | +64.1% |
| 2017 | $42.81M | +642.0% |
| 2016 | $5.77M | -73.4% |
| 2015 | $21.66M | +75.8% |
| 2014 | $12.32M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $125.10M | +27.1% | -1.2% |
| June 30, 2025 | $126.58M | +16.9% | -8.6% |
| March 31, 2025 | $138.52M | +12.0% | -8.1% |
| December 31, 2024 | $150.73M | +618.0% | +53.1% |
| September 30, 2024 | $98.45M | +236.4% | -9.1% |
| June 30, 2024 | $108.31M | +346.9% | -12.5% |
| March 31, 2024 | $123.73M | +241.5% | +489.4% |
| December 31, 2023 | $20.99M | -37.1% | -28.3% |
- Avalo Therapeutics, Inc. showed a decrease of -22.7% in Total Assets compared to the prior fiscal year.
- Over the 2014–2025 period, Avalo Therapeutics, Inc.’s total assets has grown by 845.5% (from $12.32 million to $116.46 million).
- The most recent figure is from Avalo Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: